Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 76 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted pipeline therapeutics. 

The report provides comprehensive information on the Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) 
- The report reviews Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Overview 7
Therapeutics Development 8
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Stage of Development 8
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Therapy Area 9
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Indication 10
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Companies 13
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Companies Involved in Therapeutics Development 21
AbbVie Inc 21
Abeome Corporation 22
Affibody AB 23
Cell Medica Limited 24
Eli Lilly and Company 25
Johnson & Johnson 26
Merck KGaA 27
Novartis AG 28
Orega Biotech SAS 29
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Drug Profiles 30
ABT-122 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
ABY-035 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
CNTO-6785 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
DLX-2882 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
DLX-2907 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
DLX-2909 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
ixekizumab - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
M-1095 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Monoclonal Antibody to Inhibit IL-17A for Psoriasis and Inflammation - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
OREG-203 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
secukinumab - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Dormant Projects 60
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Discontinued Products 61
Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Featured News & Press Releases 62
Aug 04, 2016: NICE draft guidance recommends new drug for people with ankylosing spondylitis 62
Jun 21, 2016: Health Canada approval of Taltz (ixekizumab) Brings Targeted Therapy to Canadians Living with Moderate-to-Severe Plaque Psoriasis 62
Jun 09, 2016: New drug clears psoriasis in clinical trials 64
Jun 08, 2016: Studies Demonstrate Lilly's Taltz (Ixekizumab) Maintained Or Achieved High Levels Of Skin Clearance For Patients With Moderate-To-Severe Plaque Psoriasis Through 60 Weeks: Results Published In The New England Journal Of Medicine 65
Jun 08, 2016: Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016 66
Jun 07, 2016: Eli Lilly and Company Announces Data on Ixekizumab At Annual European Congress Of Rheumatology 67
Jun 07, 2016: Tampa Dermatologist Launches Clinical Trial for Psoriatic Arthritis Patients 68
Jun 02, 2016: AbbVie Announces Presentation on ABT-122 at the Annual European Congress of Rheumatology 68
May 04, 2016: Affibody Announces Initial Results from a Phase I Study of ABY-035 69
May 02, 2016: Lilly's Taltz (Ixekizumab) Now Available In The U.S. For The Treatment Of Moderate-To-Severe Plaque Psoriasis 69
Apr 27, 2016: COSENTYX - first Interleukin-17A inhibitor for psoriatic arthritis and ankylosing spondylitis approved by Health Canada 71
Apr 26, 2016: Lilly announces European Commission approval for plaque psoriasis drug 71
Apr 23, 2016: OptiMed Specialty Pharmacy to Distribute Cosentyx 72
Apr 05, 2016: Diplomat Announces TALTZ Availability for the Treatment of Plaque Psoriasis 72
Mar 22, 2016: Lilly's Taltz (Ixekizumab) Receives U.S. FDA Approval For The Treatment Of Moderate-To-Severe Plaque Psoriasis 73
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by AbbVie Inc, H2 2016 21
Pipeline by Abeome Corporation, H2 2016 22
Pipeline by Affibody AB, H2 2016 23
Pipeline by Cell Medica Limited, H2 2016 24
Pipeline by Eli Lilly and Company, H2 2016 25
Pipeline by Johnson & Johnson, H2 2016 26
Pipeline by Merck KGaA, H2 2016 27
Pipeline by Novartis AG, H2 2016 28
Pipeline by Orega Biotech SAS, H2 2016 29
Dormant Projects, H2 2016 60
Discontinued Products, H2 2016 61